MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.
Follicular Lymphoma and Marginal Zone Lymphoma
DRUG: Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide|DRUG: lenalinomide
Progression-free Survival (per IRC), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years
Progression-free Survival (per Investigator), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years|Overall Survival, From date of randomization Until date of death from any cause for up to 5 years|Overall Response Rate (ORR), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years|Kaplan-Meier Estimate of Duration of Response, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years|Percentage of Participants With Disease Control, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years|Number of Participants With Treatment Emergent Adverse Events, up to the 1 month the last dose of last subject
This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.